- Jaguar Health, Inc. entered into a Securities Purchase Agreement with Brown Stone Capital Limited on **September 28, 2025**, for a private placement.  **[1585608_0001193125-25-226788_d20552dex101.htm:0]** **[1585608_0001193125-25-226788_d20552d8k.htm:1]** 
- The company agreed to sell **161,583 Common Shares** at **$1.56 per share** and **479,442 Pre-Funded Warrants** (at $1.56 minus $0.0001 per warrant) for a total purchase price of **$1,000,000**.  **[1585608_0001193125-25-226788_d20552dex101.htm:0]** **[1585608_0001193125-25-226788_d20552d8k.htm:1]** 
- Proceeds from this private placement will be used for **working capital, general corporate purposes, and the repayment of existing convertible notes**.  **[1585608_0001193125-25-226788_d20552d8k.htm:1]** 
- Jaguar Health, Inc. committed to filing a registration statement on Form S-3 by **October 9, 2025**, to register the resale of the shares and pre-funded warrant shares.  **[1585608_0001193125-25-226788_d20552d8k.htm:1]** **[1585608_0001193125-25-226788_d20552dex101.htm:28]**

Jaguar Health Enters Securities Purchase Agreement for Private Placement

- Jaguar Health is advancing **crofelemer** for human cancer therapy-related diarrhea, having filed an **orphan drug application** for metastatic breast cancer and expecting to complete a treatment trial in **2026** to support a supplemental New Drug Application.  **[1585608_2162773_2]** **[1585608_2162773_3]** 
- The company is also developing a different formulation of **crofelemer** for intestinal failure, including microvillous inclusion disease (MVID) and short bowel syndrome, with **groundbreaking Phase 2 data** showing a **27% reduction** in total parenteral support for MVID patients and an upcoming FDA meeting to discuss expedited approval.  **[1585608_2162773_4]** **[1585608_2162773_5]** 
- Jaguar Health's approved product, **Mytesi**, for chronic diarrhea in HIV/AIDS patients, is experiencing **5% annual sales growth**, and its conditionally approved veterinary product, **Canalevia CA1**, recently received a **$250,000** grant award for its confirmatory trial.  **[1585608_2162773_7]** 
- The company is actively pursuing **major corporate partnerships** to secure non-dilutive funding for its de-risked development programs, targeting significant market opportunities such as the **$4.5 billion** short bowel syndrome market.  **[1585608_2162773_2]** **[1585608_2162773_6]**

Jaguar Health Provides Update on Crofelemer Development Programs and Market Opportunities

- Jaguar Health (JAGX) has **filed for Orphan Drug Designation (ODD)** with the FDA for metastatic breast cancer, specifically for breast cancer that has metastasized to the brain, a strategy intended to expedite approval and leverage regulatory flexibility.  **[1585608_2157879_1]** **[1585608_2157879_2]** 
- The company's key asset, **crofelemer**, is an FDA-approved, plant-based drug with **156 issued patents** and no generic pathway, offering significant exclusivity.  **[1585608_2157879_1]** 
- Jaguar Health also **received a $250,000 grant** to support a confirmatory trial for Canalevia, its conditionally approved product for chemotherapy-induced diarrhea in dogs, aiming to maintain market access and potentially expand its indication.  **[1585608_2157879_2]** 
- The company is actively pursuing business development deals to secure **non-dilutive funding** for its late-stage programs, which include cancer therapy-related diarrhea and intestinal failure.  **[1585608_2157879_1]** **[1585608_2157879_2]**

Jaguar Health Files for Orphan Drug Designation and Secures Grant

- Jaguar Health, Inc. completed a **private placement** of approximately **951 shares** of Series N Perpetual Preferred Stock, raising approximately **$2.38 million**.  **[1585608_0001193125-25-201351_d947025d8k.htm:2]** 
- The private placement closed on **September 10, 2025**, with proceeds intended for **working capital, general corporate purposes, and repayment of certain existing notes**.  **[1585608_0001193125-25-201351_d947025d8k.htm:2]** 
- The Series N Preferred Stock has a **stated value of $2,500.00 per share** and is **exchangeable for Common Stock** at an exchange price of **$1.20 per share** following stockholder approval.  **[1585608_0001193125-25-201351_d947025d8k.htm:2]** **[1585608_0001193125-25-201351_d947025dex31.htm:2]** **[1585608_0001193125-25-201351_d947025dex31.htm:4]** 
- The company is required to hold a stockholder meeting within **90 days** of the closing to obtain the necessary approval for the exchange of shares and will file a registration statement on Form S-3 within **30 days** for the resale of the exchangeable shares.  **[1585608_0001193125-25-201351_d947025d8k.htm:2]** **[1585608_0001193125-25-201351_d947025dex101.htm:11]** 
- Holders of Series N Preferred Stock will **not receive any dividends**.  **[1585608_0001193125-25-201351_d947025dex31.htm:4]** **[1585608_0001193125-25-201351_d947025d8k.htm:5]**